Aligos Therapeutics, Inc. (ALGS)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $4.07
- As of
Kresmion compiles this page from ALGS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Aligos Therapeutics, Inc. (ALGS): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-06.
See the full ALGS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ALGS on one page. Preview it with sample data, then open it live with a free account.
Preview the ALGS dossierActive events for ALGS
- mediumEarnings above estimates
Q3-2026: Beat consensus by 5.6%, EPS $-2.09 vs $-2.2134 estimate
- high13F: large reduction
RENAISSANCE TECHNOLOGIES LLC cut 89% of ALGS (2026Q2)
- high13F: large increase
D. E. Shaw & Co., Inc. added +505% to ALGS (2026Q2)
- mediumEarnings above estimates
Q2-2026: Beat consensus by 87.2%, EPS $-0.14 vs $-1.095 estimate
- medium13F: new position
D. E. Shaw & Co., Inc. new position in ALGS
FREE, NO ACCOUNT
Every event on ALGS, as it fires
You are seeing 5 of 9 events recorded on ALGS since 2026-05-26.
The five above landed across 4 days. The other 4 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
ALGS positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| D. E. Shaw & Co., Inc. FundCUSIP 01626L204 · 2026Q2 | $383K | 0.00% |
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 01626L204 · 2026Q2 | $62K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ALGS
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
Going concern statement
ALGS's 10-Q filed Nov 6, 2026 states:
Our current operating plan and projected cash outflows for the upcoming periods raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements included elsewhere in this…
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on ALGS
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in ALGS on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on ALGS in the last 180 days.
Upstream: SEC EDGAR filings for ALGS
Kresmion, "Aligos Therapeutics, Inc. (ALGS) institutional holdings and SEC filings", data as of 2026-11-08, https://kresmion.com/research/ALGS. Upstream data: SEC EDGAR filings for ALGS.
Link to this data (HTML):
<a href="https://kresmion.com/research/ALGS">Aligos Therapeutics, Inc. (ALGS) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow ALGS on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to ALGS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.